GBM Specific Neutra™ Antibody Products

Are you currently facing challenges in glioblastoma therapeutic development, such as inefficient target engagement or a lack of functionally validated reagents? Creative Biolabs' GBM specific Neutra™ antibody products leverage advanced hybridoma and phage display technologies to help you develop high-specificity neutralizing antibodies, accelerating your drug discovery pipeline for brain cancers.

Introduction to GBM

Glioblastoma multiforme (GBM) represents the most common and aggressive primary malignant brain tumor in adults, characterized by rapid proliferation, extensive infiltration into surrounding brain tissue, and profound therapeutic resistance. The median survival post-diagnosis remains dismal, underscoring the critical need for novel therapeutic interventions.

• Structure

Structurally, the GBM tumor microenvironment is highly heterogeneous and complex. It is composed of a dense network of tumor cells, aberrant vasculature, hypoxic regions, and a significant immunosuppressive stromal compartment. Key structural components include the overexpressed extracellular matrix proteins that facilitate invasion and the unique perivascular niche that harbors glioma stem cells, which are pivotal for tumor recurrence.

• Related Signaling Pathways

Several dysregulated signaling pathways drive GBM pathogenesis. The Receptor Tyrosine Kinase (RTK)/Ras/Phosphoinositide 3-Kinase (PI3K) pathway is hyperactivated in the majority of cases, promoting cell survival, proliferation, and motility. The p53 and Rb tumor suppressor pathways are frequently inactivated, allowing for unchecked cell cycle progression. Additionally, angiogenesis is predominantly driven through the Vascular Endothelial Growth Factor (VEGF) signaling pathway, supporting tumor growth and metastasis.

Fig.1 RTK activation and the downstream signaling in GBM.¹

• Pathological Relevance

The disease pathology of GBM is devastating, leading to rapid neurological decline. Symptoms include severe headaches, seizures, cognitive impairment, and focal neurological deficits, significantly impacting patient's quality of life and presenting a formidable challenge in clinical management.

Application of Anti-GBM Neutralizing Antibody

• Therapeutic Development

Anti-GBM neutralizing antibodies form the core of several investigational therapeutic strategies. They are deployed to directly inhibit tumor growth by blocking key oncogenic drivers like EGFRvIII, thereby inducing apoptosis and suppressing mitogenic signaling. Furthermore, they are utilized in antibody-drug conjugates (ADCs) to deliver cytotoxic payloads directly to tumor cells, minimizing off-target effects and enhancing treatment efficacy.

• Diagnostic and Prognostic Tool

These antibodies are critical components in immunohistochemistry (IHC) and flow cytometry-based diagnostic assays, enabling the precise identification of GBM subtypes based on specific biomarker expression profiles. This allows for improved patient stratification, more accurate prognostication, and the monitoring of minimal residual disease following surgical resection and adjuvant therapy.

Our Anti-GBM Antibody Products

Antibodies targeting GBM-associated antigens, such as VEGF, EGFR, and IL-13Rα2, are at the forefront of oncological research. These high-affinity neutralizing antibodies are engineered to precisely bind their cognate antigens, blocking critical ligand-receptor interactions and downstream oncogenic signaling. They inhibit tumor cell proliferation, induce antibody-dependent cellular cytotoxicity (ADCC), suppress angiogenesis by targeting VEGF-A, and disrupt the survival mechanisms of treatment-resistant glioma stem cells. This multifaceted mode of action makes them invaluable tools for both basic research and the development of targeted immunotherapies.

Creative Biolabs provides a comprehensive portfolio of high-specificity GBM-specific Neutra™ antibodies, essential for advancing your neuro-oncology research and therapeutic programs.

Contact our scientific team today to explore how our reagents can be integrated into your workflow.

REFERENCE

1. Pearson, Joshua RD, and Tarik Regad. "Targeting cellular pathways in glioblastoma multiforme." Signal transduction and targeted therapy 2.1 (2017): 1-11. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1038/sigtrans.2017.40